Joseph Wolk - Johnson Johnson Chief Financial Officer, Executive Vice President
| JNJ Stock | USD 145.74 0.97 0.67% |
President
Mr. Joseph J. Wolk is Chief Financial Officer, Executive Vice President of the Company. He was previously Vice President, Group Finance for the Pharmaceuticals Group of Johnson Johnson, where he provided finance leadership, supporting Worldwide Chairman, Pharmaceuticals Joaquin Duato, and Chief Scientific OfficerPaul Stoffels, as a member of the Pharmaceuticals Group Operating Committee. Prior to that role, he held other finance leadership positions at Johnson Johnson as Vice President of Finance for the Medical Devices Global Supply Chain, and as Chief Financial Officer of the North America Pharmaceuticals Group, responsible for Centocor Ortho Biotech Inc. as well as U.S. Pricing Strategy and Compliance. Wolk joined Johnson Johnson in 1998 as a Finance Manager in the OrthoMcNeil Pharmaceutical organization. Prior to joining Johnson Johnson, Wolk held multiple positions of increasing responsibility at Ametek, Inc. He holds a BS degree in Finance from St. Joseph University, where he currently serves on the Haub School of Business Board of Visitors, and he also holds a Juris Doctor degree from Temple University School of Law and is a Certified Public Accountant. since 2018.
| Age | 54 |
| Tenure | 6 years |
| Address | One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 |
| Phone | 732 524 0400 |
| Web | https://www.jnj.com |
Johnson Johnson Management Efficiency
The company has Return on Asset of 0.0833 % which means that on every $100 spent on assets, it made $0.0833 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1831 %, implying that it generated $0.1831 on every 100 dollars invested. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Johnson Johnson's Return On Tangible Assets are relatively stable compared to the past year. Return On Capital Employed is expected to hike to 0.26 this year, although the value of Return On Assets will most likely fall to 0.14. At this time, Johnson Johnson's Total Current Liabilities is relatively stable compared to the past year. Liabilities And Stockholders Equity is expected to hike to about 175.9 B this year, although the value of Change To Liabilities is projected to rise to (962.5 M).Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Marilyn Purchase | Amphastar P | 64 | |
| Kevin OKeeffe | Collegium Pharmaceutical | N/A | |
| Mark Currie | Ironwood Pharmaceuticals | 63 | |
| Gordon Pugh | Alkermes Plc | 57 | |
| Rong Zhou | Amphastar P | 59 | |
| Riccardo Manetti | Dynavax Technologies | N/A | |
| James Jones | Pacira Pharmaceuticals | 51 | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| CTodd Nichols | Alkermes Plc | N/A | |
| Jason Shandell | Amphastar P | 44 | |
| Mark Stejbach | Alkermes Plc | 55 | |
| David Johnson | Dynavax Technologies | 56 | |
| Shane Cooke | Alkermes Plc | 54 | |
| Scott Braunstein | Pacira Pharmaceuticals | 52 | |
| Scott Dreyer | Collegium Pharmaceutical | 52 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Elliot Ehrich | Alkermes Plc | 57 | |
| Kelly MacDonald | Ironwood Pharmaceuticals | 34 | |
| Jacob Liawatidewi | Amphastar P | 44 | |
| John Weet | Collegium Pharmaceutical | N/A | |
| Halley Gilbert | Ironwood Pharmaceuticals | 48 | |
Management Performance
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0833 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer | ||
| Duane Arsdale, Treasurer | ||
| Mary Coleman, Independent Director | ||
| Michael Ullmann, VP, General Counsel and Member of Executive Committee | ||
| Jasmina Brooks, President Webster | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Nadja West, Independent Director | ||
| Mark Larkins, Worldwide Secretary | ||
| Vanessa Broadhurst, Executive Vice President Global Corporate Affairs | ||
| Louise Mehrotra, Vice President Investor Relations | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Ronald Williams, Independent Director | ||
| Tom Cavanaugh, Company Medicine | ||
| D Davis, Independent Director | ||
| Anne Mulcahy, Lead Independent Director | ||
| Ian Davis, Independent Director | ||
| Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee | ||
| Mark Weinberger, Independent Director | ||
| A Washington, Independent Director | ||
| Dirk Brinckman, Chief Officer | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | ||
| William Perez, Independent Director | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Marillyn Hewson, Independent Director | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| Joseph CPA, Executive CFO | ||
| Michael Bodner, Global Recovery | ||
| Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| Mary Beckerle, Independent Director | ||
| Darius Adamczyk, Independent Director | ||
| Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee | ||
| Scott Davis, Director | ||
| Hani Abouhalka, Company Digital | ||
| Ahmet Tezel, Group RD | ||
| Robert Decker, Controller Officer | ||
| Mathai Mammen, Executive Vice President Pharmaceuticals, R&D | ||
| Timothy Schmid, Executive MedTech | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| William Hait, Executive Vice President Chief External Innovation, Medical Safety, Global Public Health Officer | ||
| James Swanson, Executive Vice President, Chief Information Officer | ||
| Hubert Joly, Independent Director | ||
| Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
| Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consumer Health | ||
| Jessica Moore, Vice Relations | ||
| Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Celine Martin, Group CSS | ||
| Eugene Washington, Independent Director | ||
| Elizabeth Forminard, Executive Counsel | ||
| Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
| Guy MD, Group EMEA | ||
| Susan Lindquist, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0833 | ||||
| Profit Margin | 0.41 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 363.01 B | ||||
| Shares Outstanding | 2.41 B | ||||
| Shares Owned By Institutions | 71.24 % | ||||
| Number Of Shares Shorted | 15.94 M | ||||
| Price To Earning | 24.69 X | ||||
| Price To Book | 5.17 X |
Johnson Johnson Investors Sentiment
The influence of Johnson Johnson's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Johnson. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Johnson Johnson's public news can be used to forecast risks associated with an investment in Johnson. The trend in average sentiment can be used to explain how an investor holding Johnson can time the market purely based on public headlines and social activities around Johnson Johnson. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Johnson Johnson's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Johnson Johnson's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Johnson Johnson's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Johnson Johnson.
Johnson Johnson Implied Volatility | 78.41 |
Johnson Johnson's implied volatility exposes the market's sentiment of Johnson Johnson stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Johnson Johnson's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Johnson Johnson stock will not fluctuate a lot when Johnson Johnson's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Johnson Johnson in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Johnson Johnson's short interest history, or implied volatility extrapolated from Johnson Johnson options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Johnson Stock analysis
When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Johnson Johnson's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.106 | Dividend Share 4.7 | Earnings Share 5.2 | Revenue Per Share 33.613 | Quarterly Revenue Growth 0.073 |
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.